CN1370073A - 化学螯合剂作为药物诱发的神经肌肉传导阻滞的逆转剂的用途 - Google Patents
化学螯合剂作为药物诱发的神经肌肉传导阻滞的逆转剂的用途 Download PDFInfo
- Publication number
- CN1370073A CN1370073A CN00811655A CN00811655A CN1370073A CN 1370073 A CN1370073 A CN 1370073A CN 00811655 A CN00811655 A CN 00811655A CN 00811655 A CN00811655 A CN 00811655A CN 1370073 A CN1370073 A CN 1370073A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- conduction block
- agent
- neuromuscular conduction
- cyclophane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002738 chelating agent Substances 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 239000000126 substance Substances 0.000 title abstract description 9
- 206010029315 Neuromuscular blockade Diseases 0.000 title abstract description 4
- 239000012313 reversal agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 67
- 229920000858 Cyclodextrin Polymers 0.000 claims description 51
- 230000002232 neuromuscular Effects 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 35
- 229960003682 rocuronium bromide Drugs 0.000 claims description 33
- OYTJKRAYGYRUJK-FMCCZJBLSA-M rocuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 OYTJKRAYGYRUJK-FMCCZJBLSA-M 0.000 claims description 33
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 26
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 18
- 150000002482 oligosaccharides Chemical class 0.000 claims description 17
- 229920001542 oligosaccharide Polymers 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 241001597008 Nomeidae Species 0.000 claims description 9
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 claims description 7
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 6
- LVQTUXZKLGXYIU-GWSNJHLMSA-M rapacuronium Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)CC)[N+]2(CC=C)CCCCC2)CCCCC1 LVQTUXZKLGXYIU-GWSNJHLMSA-M 0.000 claims description 6
- 229940032712 succinylcholine Drugs 0.000 claims description 6
- WMSYWJSZGVOIJW-ONUALHDOSA-L Mivacurium chloride Chemical compound [Cl-].[Cl-].C([C@@H]1C2=CC(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(CCC=2C=C(C(=CC=2[C@H]1CC=1C=C(OC)C(OC)=C(OC)C=1)OC)OC)C)C1=CC(OC)=C(OC)C(OC)=C1 WMSYWJSZGVOIJW-ONUALHDOSA-L 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 claims description 5
- 229960003379 pancuronium bromide Drugs 0.000 claims description 5
- 229960004804 rapacuronium Drugs 0.000 claims description 5
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 claims description 5
- 229960004298 vecuronium bromide Drugs 0.000 claims description 5
- 229960002540 mivacurium Drugs 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 229960001844 tubocurarine Drugs 0.000 claims description 4
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- OOLUVSIJOMLOCB-UHFFFAOYSA-N 1633-22-3 Chemical compound C1CC(C=C2)=CC=C2CCC2=CC=C1C=C2 OOLUVSIJOMLOCB-UHFFFAOYSA-N 0.000 description 34
- 239000008186 active pharmaceutical agent Substances 0.000 description 31
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 150000001538 azepines Chemical class 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- SJLBIPLIGYWGJV-UHFFFAOYSA-N N-nitroso-N-methyl-4-aminobutyric acid Chemical compound O=NN(C)CCCC(O)=O SJLBIPLIGYWGJV-UHFFFAOYSA-N 0.000 description 13
- -1 cyclic organic compounds Chemical class 0.000 description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 11
- 229960004373 acetylcholine Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000028161 membrane depolarization Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 5
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 5
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000012440 Acetylcholinesterase Human genes 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 3
- 229940124596 AChE inhibitor Drugs 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 3
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241001505096 Rhamnus davurica Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229960001862 atracurium Drugs 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229960002655 tubocurarine chloride Drugs 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008674 Cholinergic syndrome Diseases 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000004880 oxines Chemical class 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 210000003105 phrenic nerve Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical compound ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 1
- ITUMSOXNRSAAJY-UHFFFAOYSA-N 5-chloro-2-methyl-5-oxopentanoic acid Chemical compound OC(=O)C(C)CCC(Cl)=O ITUMSOXNRSAAJY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100086436 Caenorhabditis elegans rap-1 gene Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101100420081 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-0 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019789 abdominal cramp Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical group OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950008951 atracurium besilate Drugs 0.000 description 1
- XXZSQOVSEBAPGS-UHFFFAOYSA-L atracurium besylate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 XXZSQOVSEBAPGS-UHFFFAOYSA-L 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960001437 mivacurium chloride Drugs 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000001611 motor endplate Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 229960003335 rapacuronium bromide Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940106905 robinul Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940120904 succinylcholine chloride Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
化合物1:α-环糊精(α-CD) | Wacker-Chemie GmbH,慕尼黑,德国;或ALDRICH |
化合物2:羧甲基-β-CD(DS=3.5)钠盐 | Wacker-Chemie GmbH,慕尼黑,德国 |
化合物3:2-羟基-3-三甲基胺基丙基-β-CD(DS=3.5) | Wacker-Chemie GmbH,慕尼黑,德国 |
化合物4:过2,6-二甲基-β-CD(DS=12.6) | Wacker-Chemie GmbH,慕尼黑,德国 |
化合物5:β-环糊精-磷酸钠盐(DS=3) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物6:β-环糊精-磷酸钠盐(DS=8) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物7:羧甲基-β-CD(DS=3-3.5) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物8:羧乙基-β-CD(DS=3) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物9:β-环糊精(β-CD) | Wacker-Chemie GmbH,慕尼黑,德国;或ALDRICH |
化合物10:2-羟丙基-β-CD | RBI,Natick,MA01760,USA |
化合物11:γ-环糊精-磷酸钠盐(DS=3) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物12:γ-环糊精-磷酸钠盐(DS=7) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物13:羧甲基-γ-CD(DS=3.2) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物14:羧乙基-γ-CD(DS=3.8) | CycloLab,Ltd.布达佩斯,匈牙利 |
化合物15:γ-环糊精(γ-CD) | Wacker-Chemie GmbH,慕尼黑,德国;或FLUKA |
化合物16:2-羟丙基-γ-CD)(DS=4) | RBI,Natick,MA01760,USA |
化学螯合剂 | 缔合常数(Ka,M-1) |
β-环糊精(9)γ-环糊精(15) | 3 100-3 900*10 000-20 400# |
化合物* | Roc | Vec | Pan | Miv | Atr | Cis-Atr | T-C | Sux | Rap |
1:α-环糊精(α-CD) | 1575(2) | 2610(1) | |||||||
2:羧甲基-β-CD(DS=3.5)钠盐 | 134(2) | 800(1) | |||||||
3:2-羟基-3-三甲基胺基丙基-β-CD(DS=3.5) | 518(2) | 1400(1) | |||||||
4:过2,6-二甲基-β-CD(DS=12.6) | 70(2) | 1313(4) | |||||||
5:β-环糊精-磷酸钠盐(DS=3) | 280(3) | ||||||||
6:β-环糊精-磷酸钠盐(DS=8) | 120(2) | ||||||||
7:羧甲基-β-CD(DS=3-3.5) | 139(3) | ||||||||
8:羧乙基-β-CD(DS=3) | 42(3) | 103(2) | 479(2) | 408(2) | 412(2) | ||||
9:β-环糊精(β-CD) | 20(3) | 636(1) | 1050(2) | 358(3) | |||||
10:2-羟丙基-β-CD | 33(3) | 1598(4) | |||||||
11:γ-环糊精-磷酸钠盐(DS=3) | 64(3) | 67(3) | 197(2) | 292(2) | 113(2) | 204(2) | 160(2) | 160(2) | 80(3) |
12:γ-环糊精-磷酸钠盐(DS=7) | 52(2) | ||||||||
13:羧甲基-γ-CD(DS=3.2) | 25(4) | 30(3) | 641(4) | 964(3) | 990(2) | 893(2) | 431(2) | 999(2) | 227(2) |
14:羧乙基-γ-CD(DS=3.8) | 7(3) | 25(3) | 141(3) | 399(2) | 421(2) | 1558(3) | 294(2) | 1294(2) | 43(3) |
15:γ-环糊精(γ-CD) | 4(3) | 75(4) | 186(4) | 1690(2) | 2793(4) | 1710(2) | 630(2) | 1189(2) | 57(3) |
16:2-羟丙基-γ-CD(DS=4) | 12(3) | 123(3) | 440(3) | 1674(2) | 828(2) | 878(2) | 909(2) | 1340(2) | 134(3) |
化合物 | 3.1μM罗库溴铵1 |
环糊精 | |
11:γ-环糊精-磷酸钠盐(DS=3) | 34(360) |
12:γ-环糊精-磷酸钠盐(DS=7) | 17(360) |
13:羧甲基-γ-CD(DS=3.2) | 88(180) |
14:羧乙基-γ-CD(DS=3.8) | 87(144) |
15:γ-环糊精(γ-CD) | 94(144) |
16:2-羟丙基-γ-CD(DS=4) | 71(360) |
环状寡糖 | |
24:环[(1,4)-α-L-鼠李吡喃糖基-(1,4)-α-D-甘露吡喃糖基]四糖苷 | 86(288) |
环芳 | |
17:1,7,21,27-四氧杂-9,17,29,37-四羧基[7.1.7.1]二聚二甲苯一羧酸 | 11(360) |
18:1,10,24,33-四氧杂-12,20,35,43-四羧基-[2.2.1.2.2.1]二聚二甲苯一羧酸 | 61(288) |
19:N,N’,N”,N”’-四(羧基乙酰基)-1,7,21,27-四氮杂[7.1.7.1]二聚二甲苯一羧酸 | 2.4(108) |
20:N,N’,N”,N”’-四(4-羧基丁酰基)-1,7,21,27-四氮杂[7.1.7.1]二聚二甲苯一羧酸 | 8.7(72) |
21:N,N’,N”,N”’-四(3-羧基丙酰基)-1,7,21,27-四氮杂[7.1.7.1]二聚二甲苯一羧酸 | 0(360) |
23:N,N’,N”,N”’-四(3-羧基丙酰基)-3,4,5,6,7,8,26,27,28,29,30,31-十二氢-1,10,24,33-四氮杂[2.2.1.2.2.1]二聚二甲苯一羧酸 | 90(58) |
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99306411.2 | 1999-08-13 | ||
EP99306411 | 1999-08-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1370073A true CN1370073A (zh) | 2002-09-18 |
CN1241576C CN1241576C (zh) | 2006-02-15 |
Family
ID=8241574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008116555A Expired - Lifetime CN1241576C (zh) | 1999-08-13 | 2000-08-07 | 化学螯合剂用于制备逆转临床使用的神经肌肉传导阻滞剂药物诱发的神经肌肉传导阻滞的药物的用途 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7265099B1 (zh) |
EP (1) | EP1210090B1 (zh) |
JP (1) | JP4782334B2 (zh) |
CN (1) | CN1241576C (zh) |
AR (1) | AR025103A1 (zh) |
AU (1) | AU780416B2 (zh) |
BR (1) | BR0013126A (zh) |
CA (1) | CA2380920C (zh) |
IL (1) | IL147887A0 (zh) |
MX (1) | MXPA02001545A (zh) |
WO (1) | WO2001012202A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113387798A (zh) * | 2021-05-08 | 2021-09-14 | 上海大学 | 用作逆转神经肌肉阻滞剂的水溶性柱[n]芳烃及其应用 |
CN113509486A (zh) * | 2021-06-16 | 2021-10-19 | 南开沧州渤海新区绿色化工研究有限公司 | Cca-cd共组装体在制备大分子毒素解毒药物中的应用 |
CN115057797A (zh) * | 2022-02-24 | 2022-09-16 | 上海大学 | 一种水溶性联苯芳烃的合成及生物毒素解毒的应用 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI242015B (en) * | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
WO2003077906A1 (en) * | 2002-03-18 | 2003-09-25 | Nihon University | Cyclic etheramine derivatives as medicaments for malignant tumors |
BRPI0808272A2 (pt) * | 2007-03-08 | 2014-07-08 | Chemagis Ltd | "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio" |
US20100087650A1 (en) * | 2007-03-26 | 2010-04-08 | Chemagis Ltd. | (1r,1'r)-atracurium salts separation process |
EP2155684B1 (en) * | 2007-05-01 | 2014-04-09 | Chemagis Ltd. | Process for producing cisatracurium compounds and associated intermediates |
BRPI0809892A2 (pt) * | 2007-05-01 | 2014-09-30 | Chemagis Ltd | Composto de isoquinolínio, forma cristalina, composto cristalino (vii) e método para preparar cis-atracúrio |
BRPI0811687A2 (pt) * | 2007-06-18 | 2015-02-18 | Chemagis Ltd | MÉTODO PARA SEPARAR O ISÔMETRO 1R-CIS, 1'R-CIS (cisatracúrio) DE UMA MISTURA DE ISÔMEROS DE SAIS DE (1R, 1'R) - ATRACÚRIO |
EP2176227A1 (en) * | 2007-07-09 | 2010-04-21 | Chemagis Ltd. | Process for producing cisatracurium and associated intermediates |
US8354537B2 (en) * | 2007-10-29 | 2013-01-15 | Chemagis Ltd. | R,R1-atracurium salts |
EP2283005A4 (en) * | 2008-05-01 | 2011-08-31 | Chemagis Ltd | CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF |
US8466278B2 (en) | 2008-09-22 | 2013-06-18 | Arcarios B.V. | Carboxyethylated cyclodextrin polysulfates useful as medicaments |
US11013750B2 (en) | 2017-01-20 | 2021-05-25 | Aurin Biotech Inc. | Methods for treating and preventing nociceptive pain |
EP3830184A1 (en) | 2018-08-02 | 2021-06-09 | Pliva Hrvatska D.O.O. | Solid state forms of sugammadex sodium |
US11324692B2 (en) | 2019-07-03 | 2022-05-10 | Galenicum Health S.L.U. | Method to prepare pharmaceutical compositions of suggamadex |
US11097023B1 (en) | 2020-07-02 | 2021-08-24 | Par Pharmaceutical, Inc. | Pre-filled syringe containing sugammadex |
ES2949710T1 (es) | 2020-07-03 | 2023-10-02 | Galenicum Health S L U | Método para preparar composiciones farmacéuticas |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929813A (en) | 1973-12-26 | 1975-12-30 | Interx Research Corp | Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same |
ATE113612T1 (de) | 1990-03-15 | 1994-11-15 | Tanabe Seiyaku Co | Polysulfat eines cyclodextrinderivates und verfahren zu dessen herstellung. |
US5180716A (en) | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
US5840881A (en) | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
US5767112A (en) | 1994-10-21 | 1998-06-16 | Poli Industria Chimica, S.P.A. | Muscle relaxant pharmaceutical compositions |
AU708107B2 (en) * | 1994-11-04 | 1999-07-29 | Commonwealth Scientific And Industrial Research Organisation | Method for treating animals |
US5834446A (en) | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
JP4249282B2 (ja) | 1998-02-27 | 2009-04-02 | 日本食品化工株式会社 | 新規シクロデキストリン誘導体及びその製造方法 |
-
2000
- 2000-08-07 JP JP2001516547A patent/JP4782334B2/ja not_active Expired - Lifetime
- 2000-08-07 US US10/049,393 patent/US7265099B1/en not_active Expired - Lifetime
- 2000-08-07 BR BR0013126-1A patent/BR0013126A/pt not_active Application Discontinuation
- 2000-08-07 IL IL14788700A patent/IL147887A0/xx active IP Right Grant
- 2000-08-07 CN CNB008116555A patent/CN1241576C/zh not_active Expired - Lifetime
- 2000-08-07 CA CA2380920A patent/CA2380920C/en not_active Expired - Lifetime
- 2000-08-07 EP EP00964006.1A patent/EP1210090B1/en not_active Expired - Lifetime
- 2000-08-07 MX MXPA02001545A patent/MXPA02001545A/es active IP Right Grant
- 2000-08-07 WO PCT/EP2000/007694 patent/WO2001012202A2/en active IP Right Grant
- 2000-08-07 AU AU75089/00A patent/AU780416B2/en not_active Expired
- 2000-08-11 AR ARP000104148A patent/AR025103A1/es unknown
-
2007
- 2007-07-19 US US11/780,243 patent/US20070299035A1/en not_active Abandoned
-
2009
- 2009-12-01 US US12/628,640 patent/US20100075938A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113387798A (zh) * | 2021-05-08 | 2021-09-14 | 上海大学 | 用作逆转神经肌肉阻滞剂的水溶性柱[n]芳烃及其应用 |
CN113509486A (zh) * | 2021-06-16 | 2021-10-19 | 南开沧州渤海新区绿色化工研究有限公司 | Cca-cd共组装体在制备大分子毒素解毒药物中的应用 |
CN113509486B (zh) * | 2021-06-16 | 2022-07-19 | 南开沧州渤海新区绿色化工研究有限公司 | Cca-cd共组装体在制备大分子毒素解毒药物中的应用 |
CN115057797A (zh) * | 2022-02-24 | 2022-09-16 | 上海大学 | 一种水溶性联苯芳烃的合成及生物毒素解毒的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4782334B2 (ja) | 2011-09-28 |
WO2001012202A3 (en) | 2001-11-15 |
WO2001012202A2 (en) | 2001-02-22 |
MXPA02001545A (es) | 2002-08-30 |
US20070299035A1 (en) | 2007-12-27 |
EP1210090A2 (en) | 2002-06-05 |
AU7508900A (en) | 2001-03-13 |
AU780416B2 (en) | 2005-03-17 |
US20100075938A1 (en) | 2010-03-25 |
CN1241576C (zh) | 2006-02-15 |
JP2003507335A (ja) | 2003-02-25 |
EP1210090B1 (en) | 2014-06-18 |
US7265099B1 (en) | 2007-09-04 |
IL147887A0 (en) | 2002-08-14 |
CA2380920A1 (en) | 2001-02-22 |
BR0013126A (pt) | 2002-04-23 |
CA2380920C (en) | 2011-07-19 |
AR025103A1 (es) | 2002-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1241576C (zh) | 化学螯合剂用于制备逆转临床使用的神经肌肉传导阻滞剂药物诱发的神经肌肉传导阻滞的药物的用途 | |
CN1241932C (zh) | 新的低聚糖、其制备方法及其药物组合物 | |
CN105073785B (zh) | 烷基化环糊精组合物及其制备和使用方法 | |
PL203012B1 (pl) | Pochodna 6-merkapto-cyklodekstryny, jej zastosowanie, zestaw do wywołania blokady nerwowo-mięśniowej i jej odwracania oraz kompozycja farmaceutyczna | |
UA127034C2 (uk) | Композиція мануронової дикарбонової кислоти | |
DE60211132T2 (de) | 2-alkylierte cyclodextrin-derivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung | |
US20130005684A1 (en) | Pharmaceutical composition containing cyclodextrin copolymer | |
CN1492760A (zh) | 环糊精制剂 | |
CN107459585A (zh) | 一种低分子量银耳多糖的生产方法 | |
US20070021380A1 (en) | Novel drug delivery compositions | |
AU2015390471A1 (en) | Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof | |
CN1830428A (zh) | 一种阿魏酸钠注射液及其制备方法和用途 | |
Kikuzawa et al. | Short synthesis of skeleton-modified cyclodextrin derivatives with unique inclusion ability | |
Manick et al. | Low‐Symmetry Macrocycles and Cages for Carbohydrate Recognition | |
JP2009179602A (ja) | エレウテリノシドa、b、c | |
CN102225974B (zh) | 一种双取代双正电中心的6-烷基咪唑鎓基-6-铵基-β-环糊精及其制备方法 | |
CN104530149A (zh) | 卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途 | |
JP2907457B2 (ja) | 光学異性体分割膜及び分割方法 | |
CN104447905A (zh) | 一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途 | |
CN104478959A (zh) | 含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途 | |
CN104478957A (zh) | 一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途 | |
Kean | Modified cyclodextrins and their complexes | |
CN104530150A (zh) | 含胺基苯和双葡萄糖苷结构化合物、其制备方法和用途 | |
CN104478956A (zh) | 苯基双o-葡萄糖苷衍生物、其制备方法和用途 | |
CN104478958A (zh) | 含卤代联苯双葡萄糖苷结构化合物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ORGANON NV Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20070105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: Holland Patentee after: N.V. ORGANON Address before: Holland Arnhem Patentee before: AKZO NOBEL N.V. |
|
C56 | Change in the name or address of the patentee |
Owner name: MSD OS CO., LTD. Free format text: FORMER NAME: ORGANON NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: Holland Patentee after: N.V. Organon Address before: Holland Patentee before: N.V. ORGANON |
|
ASS | Succession or assignment of patent right |
Owner name: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Free format text: FORMER OWNER: MSD OUSI CO., LTD. Effective date: 20131010 Owner name: MERCK SHARP + DOHME CORP. Free format text: FORMER OWNER: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Effective date: 20131010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131010 Address after: Haarlem Patentee after: MERCK SHARP & DOHME B.V. Address before: Haarlem Patentee before: Organon biological science Holland Co.,Ltd. Effective date of registration: 20131010 Address after: Haarlem Patentee after: Organon biological science Holland Co.,Ltd. Address before: Holland Patentee before: N.V. Organon |
|
CX01 | Expiry of patent term |
Granted publication date: 20060215 |
|
CX01 | Expiry of patent term |